Browse studies

Find your next paid study

3,234 recruiting studies matching your filters

MT2025-14: A Phase 1a/1b Study of GTB-5550, a Camelid Nanobody TriSpecific Killer Engager (camB7-H3 TriKE®), in Select Advanced Solid Tumors That Failed Prior Therapy

This is a first-in-human Phase 1a/1b trial of a B7-H3-targeted natural killer (NK) cell engager, referred to as a TriSpecific Killer Engager (TriKE), for the t…

Tri-specific Killer EngagerSolid TumorAdvanced Solid Tumor

Estimated

~$150 – $3,000

Actual pay is set by the research site.

Masonic Cancer Center, University of MinnesotaNCT07541573

Phase 3

Short Course Adjuvant Vaginal Cuff Brachytherapy (VCB) in Early Endometrial Cancer Compared to Standard of Care (SAVE)

This randomized phase III trial studies short course vaginal cuff brachytherapy to see how well it works compared with standard of care vaginal cuff brachyther…

Endometrial Clear Cell AdenocarcinomaEndometrial Endometrioid AdenocarcinomaEndometrial Serous Adenocarcinoma+6 more

Estimated

~$50 – $1,500

Actual pay is set by the research site.

University of UtahNCT03422198

Phase 1

A Phase 1/2a Study of the Safety, Tolerability, and Preliminary Clinical Activity of 177LuBetaBart, a 177Lu-Labeled Anti-B7-H3 Monoclonal Antibody, in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors

This is a Phase 1/2a dose escalation and expansion study to determine the safety, tolerability, and preliminary clinical activity of 177LuBetaBart, a lutetium-…

Castration-Resistant Prostate Cancer (CRPC)Colorectal CancerNSCLC (Non-small Cell Lung Cancer)+8 more

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Phase 1

Master Protocol: An Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of BAY 3771249 as Monotherapy or Combination With Other Cancer Treatments in Participants With Solid Tumors Harboring a KRAS G12D Mutation. Substudy Protocol: An Open-label, Multi-cohort Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of BAY 3771249 as Monotherapy and in Combination With Cetuximab in Participants With Advanced/Metastatic Colorectal Adenocarcinoma Harboring a KRAS G12D Mutation

Researchers are looking for a better way to treat people who have advanced or metastatic colorectal cancer (CRC) with a specific mutation, the G12D mutation, i…

Advanced/Metastatic Colorectal Adenocarcinoma

Estimated

~$150 – $4,500

Actual pay is set by the research site.

BayerNCT07535112

Presence of Barrett's Esophagitis in a Cohort of People With Eating Disorders Who Engage in Purging Behaviors: A Pilot Study

To better define the presence of Barrett's esophagus (BE) via non-endoscopic testing in an eating disorder cohort with purging (vomiting/rumination) behaviors

Barrett EsophagusAnorexia Nervosa, Binge Eating/Purging TypeRumination+3 more

Estimated

~$10 – $750

Actual pay is set by the research site.

Denver Health and Hospital AuthorityNCT06532734

Observational

Multi-Site Randomized Controlled Trial of a Novel Digital Application (DREAMLAND) to Improve Outcomes for Patients With Acute Myeloid Leukemia

This research study is evaluating to examine the efficacy of a novel a self-administered digital application (DREAMLAND) for improving patients' long-term qual…

Relapsed Adult Acute Myeloid LeukemiaPrimary Refractory Acute Myeloid LeukemiaHigh Risk Acute Myeloid Leukemia

Estimated

~$10 – $750

Actual pay is set by the research site.

Massachusetts General HospitalNCT06472128

Phase 4

Adjunctive Colchicine's Effect on Inflammatory Markers and Corresponding New-Onset Atrial Fibrillation Rates Post Coronary Artery Bypass Graft Procedure: A Pilot Study

This study wants to see if the medicine colchicine can help lower inflammation and reduce the chance of developing an irregular heartbeat (atrial fibrillation)…

ColchicineInflammation in Cardiac SurgeryPost Operative Atrial Fibrillation+2 more

Estimated

~$25 – $1,500

Actual pay is set by the research site.

Ayesha AtherNCT07287345

Assessment of the Efficacy of Medrol Dose Pack for Post-Concussive Headaches

This novel pilot project will assess the effectiveness of corticosteroids in treatment of acute post-concussion headache. The investigators hypothesize that th…

Post-Concussion SyndromeHeadache

Estimated

~$10 – $1,125

Actual pay is set by the research site.

Northwell HealthNCT04685772

Phase 1

Assessment of Radiation-Induced Vascular Complications in Patients With Head and Neck Cancers With PET/CT Imaging

This early phase I trial compares sodium fluoride F-18 (F-18 NaF) positron emission tomography (PET)/computed tomography (CT) to the standard of care imaging s…

Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8+13 more

Estimated

Phase 1

Magnetic Sentinel Lymph Node Mapping in Gastric Cancer, Safety and Feasibility Clinical Trial

This phase I finds out the possible benefits and/or side effects of using magnetic tracer FerroTrace and the fluorescent dye indocyanine green to identify the …

Gastric Adenocarcinoma

Estimated

~$150 – $3,000

Actual pay is set by the research site.

M.D. Anderson Cancer CenterNCT05038098

Phase 1

A Phase 1 Study of Sigvotatug Vedotin in Advanced Solid Tumors

This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe f…

Carcinoma, Non-Small Cell LungSquamous Cell Carcinoma of Head and NeckHER2 Negative Breast Neoplasms+9 more

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Seagen, a wholly owned subsidiary of PfizerNCT04389632

Phase 1

Phase 1/2 Master Study to Assess the Safety and Efficacy of PM54 in Combination With Cytotoxic and Targeted Agents for the Treatment of Advanced Solid Tumors

The primary purpose of this study is to evaluate the safety, tolerability and recommended dose (RD) of PM54 in combination with cytotoxic and targeted anticanc…

Advanced Solid Tumor

Estimated

~$150 – $4,200

Actual pay is set by the research site.

PharmaMarNCT07839819